A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor

EMPHASIS-lung: Erlotinib MALDI TOF PHAse III SIgnature in Squamous cell non-small cell lung cancer

In the EMPHASIS-lung trial, the potential of Veristrat, a clinically validated serum proteomic test, to predict response to treatment by erlotinib or docetaxel, is being assessed in pre-treated patients with advanced squamous cell lung carcinoma.

Recruitment was terminated prematurely due to an accrual rate that was deemed insufficient and publication of controversial new data from another study. No safety concerns led to the decision to close accrual. Treatment and follow-up continued as specified in the protocol.

Trial Scheme



Primary Endpoint: Progression free survival
Secondary Endpoints:

Overall survival

Toxicities of treatment

Objective response rate

Disease control rate

Target Sample Size: 500 Patients 
Final Accrual: 81 Patients
Protocol Release Date: June 2012
Trial Activation Date: August 2012
First Patient In: 14 January 2013
Accrual Closure Date: 31 January 2014
Global Trial Completion Date: 19 November 2015

Trial Organisation

Trial Chairs: Egbert Smit and Solange Peters
Sponsor: ETOP
Coordinating Group: ETOP
Participating Groups: CECOG, HORG, ICORG, NVALT, SAKK and SLCG   
Participating Countries:
Austria, Belgium, Denmark, Greece, Hungary, Ireland, Israel, Italy, Netherlands, Spain, Switzerland  and United Kingdom

EudraCT number: 2011-004481-15

ClinicalTrials.gov: NCT01652469 



ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.